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Previous in vivo studies have reported caspofungin dose escalation to be effective against Candida glabrata
with reduced susceptibility. We hypothesized that higher doses of caspofungin would be effective against
invasive candidiasis caused by the more virulent species Candida albicans, including isolates resistant to this
echinocandin. Immunocompetent mice were inoculated with one of three C. albicans isolates, including one
susceptible and two resistant isolates with different FKS1 hot spot 1 point mutations. Mice received daily
caspofungin treatment for 7 days and were then followed off therapy for 2 weeks to assess survival. Kidney
tissue and blood were collected, and fungal burden and serum (133)--D-glucan were measured. Significant
differences in virulence were observed among the three C. albicans isolates, which translated into differences in
responses to caspofungin. The most virulent of the resistant isolates studied (isolate 43001; Fks1p F641S) did
not respond to caspofungin doses of up to 10 mg/kg of body weight, as there were no differences in survival
(survival range, 0 to 12% with treatment), tissue burden, or (133)--D-glucan concentration compared to those
for untreated controls. Higher doses of caspofungin did improve survival against the second resistant isolate
(53264; Fks1p S645P) that demonstrated reduced virulence (5 and 10 mg/kg; 80% survival). In contrast,
caspofungin doses as low as 1 mg/kg improved survival (85 to 95%) and reduced tissue burden and (133)-
-D-glucan concentration against the susceptible isolate (ATCC 90028). These data suggest that caspofungin
dose escalation for invasive candidiasis may not be consistently effective against resistant C. albicans isolates,
and this may be associated with the virulence of the strain.
Echinocandins are safe and effective for the treatment of
invasive candidiasis. In clinical trials at approved doses, these
agents have been shown to have response rates of between 70
and 75% (15, 20, 25, 26). Overall, the toxicity profile of these
agents is quite favorable, with reported adverse event rates
similar to that of fluconazole and lower than those of ampho-
tericin B formulations (15, 20, 29). In fact, a recent study
demonstrated that daily doses of caspofungin of 150 mg, or
three times the recommended daily dose of 50 mg, were safe
and well tolerated (3). Similarly, high doses of micafungin have
also been shown to be relatively well tolerated, with few tox-
icities in different patient populations, including patients with
hematologic malignancies undergoing stem cell transplanta-
tion and children (12, 30, 31).
As is common with most antimicrobials, isolates of different
fungal species have developed resistance to echinocandins.
Case reports of reduced in vitro potency and associated clinical
failures for each member of this class against different Candida
species have been published previously (9–11, 14, 17, 19, 33).
This reduced potency is associated with mutations within the
FKS1 gene leading to amino acid changes within the glucan
synthase enzyme Fks1p (27). Due to their excellent safety
profile, some have considered dose escalation of echinocandins
as a potential means to overcome resistance. Our group has
previously reported that this strategy with caspofungin may
overcome in vitro resistance in Candida glabrata (5, 39). How-
ever, it is unknown whether dosage escalation would be effec-
tive against the more virulent species Candida albicans. Our
objective was to measure the in vivo efficacy of caspofungin
dosage escalation in the treatment of invasive candidiasis
caused by C. albicans clinical isolates resistant to caspofungin
due to defined mutations in FKS1. We hypothesized that this
strategy would be effective at improving survival and reducing
tissue fungal burden.
(This work was presented in part at the 50th Interscience
Conference on Antimicrobial Agents and Chemotherapy, Bos-
ton, MA, 2010.)
MATERIALS AND METHODS
Isolates and antifungal agents. Two caspofungin-resistant C. albicans clinical
isolates, 53264 and 43001, were obtained from the Fungus Testing Laboratory at
the University of Texas Health Science Center at San Antonio. Candida albicans
ATCC 90028 served as the susceptible, wild-type isolate for this study. The
isolates were subcultured twice onto Sabouraud dextrose agar prior to in vitro
and in vivo studies. For in vivo studies, the isolates were also grown in brain heart
infusion broth overnight prior to animal inoculation.
In vitro growth, susceptibility testing, and determination of FKS1 point mu-
tations. The in vitro growth rates of isolates 53264 and 43001 were determined by
measuring the change in optical density at 530 nm with the use of a microplate
spectrophotometer over a 24-h period. The isolates were adjusted to an inoculum
of 1  106 CFU/ml and added in duplicate to RPMI medium plus 0.165 M
MOPS (morpholinepropanesulfonic acid) (pH 7.0) or half-strength RPMI me-
dium diluted with sterile distilled water to a final inoculum of 0.5  103 to 3 
103 CFU/ml in a 96-well cell culture plate. The plate was incubated with shaking
at 37°C for 24 h, and optical density measurements were recorded every hour.
The susceptibility of each isolate to caspofungin was determined using CLSI
M27-A3 guidelines (6), and the caspofungin MIC was read as the concentration
that resulted in a significant reduction in growth compared to the growth control
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after 24 h. The point mutations for the two isolates with reduced susceptibility
have previously been reported (Table 1) (36).
Murine model of invasive candidiasis. Immunocompetent outbred ICR mice
(Harlan) weighing between 20 and 25 g were used and had access to food and
water ad libitum. For all studies, mice were inoculated via the tail vein with a
0.2-ml volume of C. albicans cells. In the initial survival studies, mice were
inoculated with each C. albicans isolate with different inocula ranging from 5.0 
105 to 1.1  107 cells/animal. Mice were then followed until day 21 postinocu-
lation to assess survival. Any animal that appeared moribund was humanely
euthanized, and death was recorded as occurring the next day. The research staff
who evaluated the mice was blinded to the virulence of the isolates, and mor-
bidity was judged using objective criteria specified a priori. In caspofungin treat-
ment studies, all mice were infected intravenously with a 0.2-ml volume with one
of the three C. albicans isolates at an inoculum of 1  106 CFU/mouse on day
0. Treatment with intraperitoneal caspofungin (1, 5, or 10 mg/kg of body weight
per day) began 24 h after inoculation and continued through day 7 postinocu-
lation. In fungal burden studies, mice from each treatment group and untreated
controls were humanely euthanized on days 1, 5, 6, and 7 postinoculation and
blood and kidneys were collected. Kidneys from each animal were homogenized
in sterile saline supplemented with antibiotics, and serial dilutions were prepared
and plated in duplicate onto Sabouraud dextrose agar. After 24 h of incubation
at 37°C, the colonies were counted and the numbers of CFU per gram of tissue
were calculated. In survival studies, caspofungin was also continued through day
7, and mice were then followed off therapy until day 21 postinoculation to assess
survival. In the initial survival studies that evaluated virulence, each inoculum
level for each isolate consisted of 10 mice. All treatment studies were con-
ducted in duplicate on separate occasions to ensure the reproducibility of the
results. The total number of mice in the survival studies was 20 per treatment
group, while fungal burden experiments consisted of 6 mice per group at each
time point. This animal protocol was approved by the Institutional Animal Care
and Use Committee at the University of Texas Health Science Center at San
Antonio, and all animals were maintained in accordance with the American
Association for Accreditation of Laboratory Animal Care (23).
Serum (133)--D-glucan assessment. (133)--D-Glucan concentrations were
measured within the serum samples collected from 6 mice per group on days 1,
5, 6, and 7 postinoculation using a commercially available kit (Fungitell; Asso-
ciates of Cape Cod, East Falmouth, MA). Briefly, 5 l of each sample was
transferred in duplicate to a 96-well cell culture tray and processed according to
the manufacturer’s instructions. The mean rate of change in optical density at
405 nm for each sample was read over 40 min with a microplate spectrophotom-
eter (Synergy HT; Biotek Instruments, Inc., Winooski, VT), and unknowns were
interpolated from a standard curve.
Histopathology. To assess the extent of fungal burden and damage within the
tissues, kidneys separate from those used to assess fungal burden were collected
from 2 mice per group on days 5, 6, and 7 postinoculation and placed into 10%
buffered formaldehyde. The kidneys were embedded in paraffin wax, sectioned,
and stained with Gomori methenamine silver (GMS). Kidney sections were
viewed by light microscopy for the presence of infecting organisms.
Statistical analysis. Survival was plotted by Kaplan-Meier analysis, and dif-
ferences in median survival time and survival rates among groups were analyzed
by the log rank test and Fisher’s exact test, respectively. Differences in serum
(133)--D-glucan concentrations and kidney fungal burden (CFU/g) were as-
sessed for significance by analysis of variance with Tukey’s posttest for multiple
comparisons. A P value of 0.05 was considered statistically significant for all
comparisons.
RESULTS
In vitro susceptibility and growth rates. The objective of this
study was to assess the in vivo effectiveness of higher doses of
caspofungin against C. albicans isolates that are resistant to
caspofungin. To achieve this objective, we used two resistant
isolates and one susceptible strain, which served as a positive
control in our murine model of invasive candidiasis. As shown
in Table 1, the two resistant isolates had caspofungin MICs of
4 g/ml. In addition, the resistant isolates had different point
mutations within FKS1, resulting in different amino acid
changes in hot spot 1 of Fks1p. We also assessed the in vitro
fitness of the isolates by comparing their growth rates over
time. As demonstrated in Fig. 1, the growth curves for ATCC
90028, 53264, and 43001 in RPMI medium were nearly super-
imposable over the first 14 h, after which the growth rate of
43001 was higher than those of 53264 and ATCC 90028. In the
reduced-nutrient environment of half-strength RPMI medium,
the growth rates were lower but similar among the three iso-
lates. The differences in in vitro fitness between these isolates
did suggest that differences in growth in vivo could be ob-
served. However, similarities in the nutrient-limited environ-
ment suggested that they would be good choices for the eval-
uation of the in vivo effectiveness of caspofungin dosage
escalation.
In vivo virulence. Significant differences in virulence were
observed among the 3 C. albicans isolates. ATCC 90028 was
the most virulent isolate at the lowest inoculum level (5.0  105
to 6.8  105 cells/animal) (Fig. 1). The median survival time of
this wild-type isolate (7 days) was significantly shorter than that
observed for both 43001 (15 days; P  0.022) and 53264 (20.5
days; P  0.001). Significant differences in virulence were also
observed between the two caspofungin-resistant isolates. For
these two isolates, 43001 was found to be more virulent. Nei-
ther resulted in 100% mortality at the lowest inoculum level.
However, at the next inoculum level assessed (0.9  106 to
1.0  106 cells/animal), the median survival time in mice in-
fected with 43001 (8.5 days) was significantly shorter than that
observed for 53264 (20 days; P  0.02). In addition, 30% of
animals infected with 53264 survived to the study endpoint
compared with none infected with 43001. No differences in
survival were found between ATCC 90028 and 43001 at this
inoculum level. However, the median survival time for ATCC
90028 (9 days) was significantly shorter than that observed for
53264 (P  0.022). At the highest inoculum levels tested (4.7 
106 and 1.1  107 cells/animal for 43001 and 53264, respec-
tively), the median survival time in mice infected with 43001
was very short (2.5 days) and no animal survived past day 4
postinoculation. In contrast, the median survival time for iso-
late 53264 was longer (7 days; P  0.0001), although all ani-
mals did succumb to infection by day 15.
In vivo survival in animals treated with escalating doses of
caspofungin. Differences in in vivo virulence between the two
resistance isolates appeared to influence the effectiveness of
caspofungin therapy. Against the susceptible isolate, ATCC
90028, caspofungin was effective at all doses tested. Each dose
prolonged the median survival time (21 days) and increased
the percentage of animals surviving until the study endpoint
(range, 85 to 95%) compared to those for untreated controls (9
days and 30%, respectively; P  0.0001 for all comparisons)
TABLE 1. In vitro susceptibilities and FKS1 point mutations against
each of the three Candida albicans isolates studieda
Isolate MIC (g/ml) FKS1 genemutation Amino acid change
ATCC 90028 0.125 None Wild type
53264 4 T1933C S645P
43001 4 T1922C F641S
a MICs were measured after 24 h of incubation as the lowest concentrations of
caspofungin that resulted in significant inhibition of growth. FKS1 mutations
were determined by dideoxy sequencing as previously described (36).
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(Fig. 2). Against isolate 53264, caspofungin doses of 5 and 10
mg/kg improved the median survival time and overall survival
percentage (21 days and 80% for both doses) compared to
those for untreated controls (17.5 days and 34%; P  0.01)
(Fig. 2). Although 60% of mice treated with 1 mg/kg caspo-
fungin survived until day 21, this was not significantly different
from the survival time of untreated controls due to the high
survival rate observed in this group. The results for isolate
43001 were quite different. No dose of caspofungin resulted in
a survival benefit in mice infected with this resistant strain. As
shown in Fig. 2, the median survival time ranged between 5 and
7 days for untreated controls and all caspofungin groups. In
addition, caspofungin did not significantly improve the per-
centage of animals surviving until day 21 postinoculation at any
dose.
Tissue fungal burden and serum (133)--D-glucan. In
agreement with the survival data, each caspofungin dosage
level significantly reduced both tissue fungal burden and
(133)--D-glucan concentration compared to those for un-
treated controls infected with the susceptible isolate, ATCC
90028 (Fig. 3). These reductions in CFU counts within the
kidneys and serum (133)--D-glucan concentrations were sig-
nificant on day 5 postinoculation (means ranging from 2.4 to
4.3 log10 CFU/g and 424 to 841 pg/ml for the caspofungin
treatment groups versus 6.0 log10 CFU/g and 1,170 pg/ml for
untreated controls, respectively) and were further decreased
FIG. 1. In vitro growth rates and initial inoculum studies used to assess the virulence of Candida albicans isolates with echinocandin resistance.
Isolates ATCC 90028, 53264, and 43001 were inoculated into RPMI medium plus 0.165 M MOPS growth medium and RPMI medium diluted to
half-strength with sterile distilled water, and the change in optical density (O.D.) at 530 nm was measured every hour over a 24-h period. In the
initial studies to assess virulence, immunocompetent mice were inoculated with isolates ATCC 90028, 53264, and 43001 at different inocula ranging
from 5.0  105 to 1.1  107 cells/animal. Animals were then followed until day 21 to assess survival. Any animal that appeared moribund was
humanely euthanized, and death was recorded as occurring the next day. Each inoculum level for each isolate consisted of 10 mice.
FIG. 2. Survival in mice inoculated with Candida albicans isolates ATCC 90028, 53264, and 43001. Treatment groups consisted of mice that
received intraperitoneal caspofungin (1, 5, or 10 mg/kg per day) or untreated controls, and therapy began 24 h after inoculation and continued until
day 7 postinoculation. Mice were then followed off therapy until day 21. Any animal that appeared moribund was humanely euthanized, and death
was recorded as occurring the next day. Each group consisted of 20 mice.
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on days 6 and 7. By day 6, the fungal burden in the 5- and
10-mg/kg dosage groups had fallen by 3 logs and was no
longer detectable in mice that were administered 10 mg/kg
caspofungin.
In contrast to the susceptible isolate, caspofungin was inef-
fective at reducing fungal burden within the kidneys of mice
infected with resistant isolate 53264 (Fig. 3). The CFU counts
at all dosage levels at all time points tested (means ranging
from 3.6 to 5.1 log10 CFU/g) were not significantly different
from those observed for untreated controls (4.5 to 5.2 log10
CFU/g). Interestingly, trends toward reductions in serum
(133)--D-glucan concentrations compared to those mea-
sured on day 1 postinoculation were observed in all groups,
including untreated controls. Against isolate 43001, caspofun-
gin was ineffective at improving either marker of infection. In
agreement with the lack of a survival benefit, high caspofungin
doses did not lead to reductions in fungal burden with the
kidneys or serum (133)--D-glucan concentrations compared
to those for untreated controls.
Histopathology. Overall, the observations made from histo-
pathology analysis supported the fungal burden results. As
shown in Fig. 4, each caspofungin dose markedly reduced the
amount of infecting organisms within the kidneys of mice in-
oculated with ATCC 90028. In mice infected with 53264, or-
ganisms could still be observed within the kidneys at all caspo-
fungin dose levels. Interestingly, the morphology of the
Candida cells appeared to be changed for the two doses that
did improve survival (5 and 10 mg/kg). For histopathology
analysis, the cells were blunted and somewhat distorted com-
pared to the hyphae observed in untreated controls and mice
treated with 1 mg/kg caspofungin. This was especially evident
in mice that received 10 mg/kg caspofungin. In contrast, robust
hyphae within the kidney tissue were observed in all groups of
mice that were infected with 43001, the isolate that was also the
FIG. 3. Changes in serum (133)--D-glucan concentration (pg/ml) and kidney tissue fungal burden (CFU/g) over time in mice infected
intravenously with C. albicans isolates ATCC 90028, 53264, and 43001. Groups consisted of untreated controls and mice that received daily
intraperitoneal doses of caspofungin (CFG) at 1, 5, or 10 mg/kg beginning at day 1 postinoculation. Animals were humanely euthanized on days
1, 5, 6, and 7 postinoculation, and sera and kidneys were harvested. Each group consisted of 6 mice per dose per time point. Mean values 
standard errors of the means are presented.
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most virulent in survival studies. These observations are con-
sistent with the lack of a survival benefit and no reductions in
tissue burden for any caspofungin dosage level against this
resistant strain.
DISCUSSION
Dose escalation of echinocandins has been proposed as a
means to improve response rates in patients with invasive fun-
gal infections. The rationale for this approach is based on the
concentration-dependent pharmacodynamic activity for mem-
bers of this class as well as the long half-lives and favorable
adverse-effect profiles that are observed clinically. Previous
studies with micafungin and caspofungin have demonstrated
that doses of these agents greater than those currently ap-
proved for clinical use are relatively safe with no significant
toxicities reported (3, 12, 30, 31).
Although there are no clinical data demonstrating that this
strategy results in improved outcomes, in vivo studies have
supported this approach. Taking into account the concentra-
tion-dependent activity and long half-lives of these agents, our
group reported that high single doses of caspofungin and the
investigational agent aminocandin (5 and 30 mg/kg) were ef-
fective at improving survival and reducing tissue fungal burden
in mice infected with a susceptible C. albicans isolate when
administered 7 days prior to inoculation (22). Two in vivo
studies have also demonstrated that echinocandin dose esca-
lation may be effective against resistant C. glabrata isolates. We
have previously shown that daily caspofungin doses of 5 and 10
mg/kg were effective at reducing CFU counts in mice with
invasive candidiasis caused by a C. glabrata isolate despite
reduced potency, as demonstrated by elevated MIC values and
limited activity as measured by in vitro pharmacodynamic as-
says (7, 39). Similarly, Brzankalski et al. reported that high
daily doses of caspofungin (1.4 mg/kg) were effective in
reducing fungal burden in mice infected with this same
C. glabrata isolate (MIC, 4 g/ml) (5). However, this strategy
was ineffective against a second C. glabrata isolate for which
the caspofungin MIC was higher (16 g/ml).
The objective of the current study was to measure the in vivo
efficacy of high caspofungin doses against caspofungin-resis-
tant C. albicans isolates. Our results demonstrate that the ef-
fectiveness of this strategy may be isolate dependent. Although
higher doses of this echinocandin did improve survival against
one of the resistant isolates studied, this was probably influ-
FIG. 4. Representative histopathological sections of mouse kidneys. Mice were inoculated intraperitoneally with C. albicans isolates ATCC
90028, 53264, and 43001, and daily treatment with caspofungin (CFG) (1, 5, or 10 mg/kg administered by intraperitoneal injection) began at day
1 postinoculation. Two mice from the untreated control group and each caspofungin dose level were humanely euthanized on days 5, 6, and 7
postinoculation, and the kidneys were processed for histopathology. Sections were viewed by light microscopy at a magnification of 200 or 400.
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enced by the reduced in vivo fitness and virulence of this strain.
Infection with 53264 did not result in 100% mortality unless
mice were inoculated with a very high number of cells (107
cells/animal), and serum (133)--D-glucan levels trended
downward over time in all groups, including untreated con-
trols. The decline in this surrogate marker of infection may
reflect a reduced in vivo fitness for this isolate, which may be
associated with the reduced virulence observed in the initial
inoculum studies. The reasons for this reduced virulence and
fitness are unknown; however, these results are consistent with
those of other investigators that have reported reduced viru-
lence in echinocandin-resistant C. albicans isolates. Ben-Ami
et al. reported reduced in vitro fitness, compensatory increases
in cell wall chitin, and an impaired capacity for yeast-to-hypha
transformation in echinocandin-resistant C. albicans isolates
with homozygous mutations in FKS1 (2). These in vitro findings
were associated with reduced virulence in both Drosophila and
murine models of invasive candidiasis. From our results, it is
unclear whether an increase in cell wall chitin is associated with
reduced virulence, as this was not evaluated. However, hyphae
were present during histopathology analysis of the kidneys of
mice infected with 53264 in both the uninfected control and
low-dose caspofungin groups. In contrast, in mice that received
higher doses of caspofungin, the Candida cells within the kid-
neys had a distorted appearance. This observation is consistent
with previous reports of changes in cell morphology in Candida
species exposed to echinocandins in vitro and may reflect
changes in cell wall architecture due to deficiencies in (133)-
-D-glucan levels (4, 38), as well as increases in cell wall chitin,
which has been reported to occur in Candida species in re-
sponse to echinocandin exposure (8, 21, 28, 32).
In contrast, no dose of caspofungin resulted in improve-
ments in survival or reductions in fungal burden in mice in-
fected with 43001, the more virulent of the resistant isolates in
our study. In addition, no significant reductions in serum
(133)--D-glucan concentration were observed with caspofun-
gin treatment, and concentrations of this surrogate marker
remained elevated (500 pg/ml) in all groups at all time
points, which may be reflective of the enhanced in vivo fitness
of this isolate. This observation may also have implications for
the host response, as unmasking of -glucans by echinocandins
influences innate immunity due to recognition of this cell wall
component by dectin-1 on macrophages, neutrophils, and den-
dritic cells (13, 16, 24, 34, 35). Although it is expected that the
combination of caspofungin and the innate immune response
would work in synergy against infections caused by Candida
species, it is unknown if or how echinocandin resistance would
influence -glucan unmasking, the host immune response, and,
potentially, the pathogenesis of invasive candidiasis. Against
isolate 53264, it is possible that the immune response in our
immunocompetent mice could have limited the in vivo fitness
and virulence. However, this does not appear to have occurred
against isolate 43001. Although one may speculate that the
differences in FKS1 point mutations may have influenced vir-
ulence or in vivo fitness, no conclusions can be made from
these results due to the limited number of isolates evaluated.
One limitation of the current study is that we did not assess the
pharmacokinetics of high-dose caspofungin in our model. How-
ever, the doses that were used have been reported by others to
result in clinically achievable concentrations (1 mg/kg), and the
higher doses of 5 and 10 mg/kg have the potential to result in
overall exposures at least two to three times higher than that
achieved with the recommended clinical maintenance dose of
50 mg, as measured by area under the concentration-time
curve (AUC) values (1, 18, 37). Additional studies are needed
to determine whether even higher caspofungin exposures
would be effective in overcoming the resistance and virulence
observed with isolate 43001.
Overall, the results of this study suggest that caspofungin
dose escalation is not consistently effective against C. albicans
isolates that are resistant to this echinocandin. This lack of
effect may be related to the in vivo fitness and virulence of
individual isolates, which cannot be discerned from MIC val-
ues. Further work is warranted to understand how different
FKS1 mutations may impact virulence and thus the response to
antifungal therapy.
ACKNOWLEDGMENTS
This work was supported in part by a research grant from the
Investigator-Initiated Studies Program of Merck & Co., Inc.
The opinions expressed here are those of the authors and do not
necessarily represent those of Merck & Co., Inc.
We thank Marcos Olivo, Randall Armstrong, Philip Graves, and
Ashley Collazo for their assistance with the experiments.
N.P.W. has received research support from Pfizer, Schering-Plough,
Merck, Basilea, and Astellas. T.F.P. has received research support
from Basilea, Astellas, Merck, Pfizer, Schering-Plough, and Nektar
Therapeutics and has served as a consultant for Basilea, Merck, Pfizer,
and Toyama.
REFERENCES
1. Andes, D., et al. 2010. In vivo comparison of the pharmacodynamic targets
for echinocandin drugs against Candida species. Antimicrob. Agents Che-
mother. 54:2497–2506.
2. Ben-Ami, R., et al. 2009. Mutations in Candida albicans FKS1 conferring
resistance are associated with attenuated virulence, abstr. M-446. Abstr. 49th
Intersci. Conf. Antimicrob. Agents Chemother., San Francisco, CA.
3. Betts, R. F., et al. 2009. A multicenter, double-blind trial of a high-dose
caspofungin treatment regimen versus a standard caspofungin treatment
regimen for adult patients with invasive candidiasis. Clin. Infect. Dis. 48:
1676–1684.
4. Bowman, J. C., et al. 2002. The antifungal echinocandin caspofungin acetate
kills growing cells of Aspergillus fumigatus in vitro. Antimicrob. Agents
Chemother. 46:3001–3012.
5. Brzankalski, G. E., et al. 2008. Evaluation of aminocandin and caspofungin
against Candida glabrata including isolates with reduced caspofungin suscep-
tibility. J. Antimicrob. Chemother. 62:1094–1100.
6. CLSI. 2008. Reference method for broth dilution antifungal susceptibility
testing of yeasts, 3rd ed. Approved standard (M27-A3). Clinical and Labo-
ratory Standards Institute, Wayne, PA.
7. Cota, J., et al. 2006. In vitro pharmacodynamics of anidulafungin and caspo-
fungin against Candida glabrata isolates, including strains with decreased
caspofungin susceptibility. Antimicrob. Agents Chemother. 50:3926–3928.
8. Cota, J. M., et al. 2008. Increases in SLT2 expression and chitin content are
associated with incomplete killing of Candida glabrata by caspofungin. An-
timicrob. Agents Chemother. 52:1144–1146.
9. Garcia-Effron, G., S. K. Katiyar, S. Park, T. D. Edlind, and D. S. Perlin.
2008. A naturally occurring proline-to-alanine amino acid change in Fks1p in
Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis ac-
counts for reduced echinocandin susceptibility. Antimicrob. Agents Che-
mother. 52:2305–2312.
10. Garcia-Effron, G., D. P. Kontoyiannis, R. E. Lewis, and D. S. Perlin. 2008.
Caspofungin-resistant Candida tropicalis strains causing breakthrough fun-
gemia in patients at high risk for hematologic malignancies. Antimicrob.
Agents Chemother. 52:4181–4183.
11. Hakki, M., J. F. Staab, and K. A. Marr. 2006. Emergence of a Candida krusei
isolate with reduced susceptibility to caspofungin during therapy. Antimi-
crob. Agents Chemother. 50:2522–2524.
12. Hiemenz, J., et al. 2005. Pharmacokinetic and maximum tolerated dose study
of micafungin in combination with fluconazole versus fluconazole alone for
prophylaxis of fungal infections in adult patients undergoing a bone marrow
or peripheral stem cell transplant. Antimicrob. Agents Chemother. 49:1331–
1336.
VOL. 55, 2011 CASPOFUNGIN VERSUS RESISTANT CANDIDA ALBICANS 3259
13. Hohl, T. M., M. Feldmesser, D. S. Perlin, and E. G. Pamer. 2008. Caspo-
fungin modulates inflammatory responses to Aspergillus fumigatus through
stage-specific effects on fungal beta-glucan exposure. J. Infect. Dis. 198:176–
185.
14. Krogh-Madsen, M., M. C. Arendrup, L. Heslet, and J. D. Knudsen. 2006.
Amphotericin B and caspofungin resistance in Candida glabrata isolates
recovered from a critically ill patient. Clin. Infect. Dis. 42:938–944.
15. Kuse, E. R., et al. 2007. Micafungin versus liposomal amphotericin B for
candidaemia and invasive candidosis: a phase III randomised double-blind
trial. Lancet 369:1519–1527.
16. Lamaris, G. A., et al. 2008. Caspofungin-mediated beta-glucan unmasking
and enhancement of human polymorphonuclear neutrophil activity against
Aspergillus and non-Aspergillus hyphae. J. Infect. Dis. 198:186–192.
17. Laverdiere, M., et al. 2006. Progressive loss of echinocandin activity follow-
ing prolonged use for treatment of Candida albicans oesophagitis. J. Anti-
microb. Chemother. 57:705–708.
18. Louie, A., et al. 2005. Pharmacodynamics of caspofungin in a murine model
of systemic candidiasis: importance of persistence of caspofungin in tissues
to understanding drug activity. Antimicrob. Agents Chemother. 49:5058–
5068.
19. Miller, C. D., B. W. Lomaestro, S. Park, and D. S. Perlin. 2006. Progressive
esophagitis caused by Candida albicans with reduced susceptibility to caspo-
fungin. Pharmacotherapy 26:877–880.
20. Mora-Duarte, J., et al. 2002. Comparison of caspofungin and amphotericin
B for invasive candidiasis. N. Engl. J. Med. 347:2020–2029.
21. Munro, C. A., et al. 2007. The PKC, HOG and Ca2	 signalling pathways
co-ordinately regulate chitin synthesis in Candida albicans. Mol. Microbiol.
63:1399–1413.
22. Najvar, L. K., et al. 2008. Therapeutic and prophylactic efficacy of amino-
candin (IP960) against disseminated candidiasis in mice. Clin. Microbiol.
Infect. 14:595–600.
23. National Research Council. 1996. Guide for the care and use of laboratory
animals. National Academy Press, Washington, DC.
24. Netea, M. G., G. D. Brown, B. J. Kullberg, and N. A. Gow. 2008. An
integrated model of the recognition of Candida albicans by the innate im-
mune system. Nat. Rev. Microbiol. 6:67–78.
25. Pappas, P. G., et al. 2009. Clinical practice guidelines for the management of
candidiasis: 2009 update by the Infectious Diseases Society of America. Clin.
Infect. Dis. 48:503–535.
26. Pappas, P. G., et al. 2007. Micafungin versus caspofungin for treatment of
candidemia and other forms of invasive candidiasis. Clin. Infect. Dis. 45:
883–893.
27. Park, S., et al. 2005. Specific substitutions in the echinocandin target Fks1p
account for reduced susceptibility of rare laboratory and clinical Candida sp.
isolates. Antimicrob. Agents Chemother. 49:3264–3273.
28. Pfaller, M., J. Riley, and T. Koerner. 1989. Effects of cilofungin (LY121019)
on carbohydrate and sterol composition of Candida albicans. Eur. J. Clin.
Microbiol. Infect. Dis. 8:1067–1070.
29. Reboli, A. C., et al. 2007. Anidulafungin versus fluconazole for invasive
candidiasis. N. Engl. J. Med. 356:2472–2482.
30. Seibel, N. L., et al. 2005. Safety, tolerability, and pharmacokinetics of mica-
fungin (FK463) in febrile neutropenic pediatric patients. Antimicrob. Agents
Chemother. 49:3317–3324.
31. Sirohi, B., et al. 2006. A study to determine the safety profile and maximum
tolerated dose of micafungin (FK463) in patients undergoing haematopoi-
etic stem cell transplantation. Bone Marrow Transplant. 38:47–51.
32. Stevens, D. A., M. Ichinomiya, Y. Koshi, and H. Horiuchi. 2006. Escape of
Candida from caspofungin inhibition at concentrations above the MIC
(paradoxical effect) accomplished by increased cell wall chitin; evidence for
beta-1,6-glucan synthesis inhibition by caspofungin. Antimicrob. Agents
Chemother. 50:3160–3161.
33. Thompson, G. R., III, et al. 2008. Development of caspofungin resistance
following prolonged therapy for invasive candidiasis secondary to Candida
glabrata infection. Antimicrob. Agents Chemother. 52:3783–3785.
34. Wheeler, R. T., and G. R. Fink. 2006. A drug-sensitive genetic network masks
fungi from the immune system. PLoS Pathog. 2:e35.
35. Wheeler, R. T., D. Kombe, S. D. Agarwala, and G. R. Fink. 2008. Dynamic,
morphotype-specific Candida albicans beta-glucan exposure during infection
and drug treatment. PLoS Pathog. 4:e1000227.
36. Wiederhold, N. P., J. L. Grabinski, G. Garcia-Effron, D. S. Perlin, and S. A.
Lee. 2008. Pyrosequencing to detect mutations in FKS1 that confer reduced
echinocandin susceptibility in Candida albicans. Antimicrob. Agents Che-
mother. 52:4145–4148.
37. Wiederhold, N. P., et al. 2004. Pharmacodynamics of caspofungin in a murine
model of invasive pulmonary aspergillosis: evidence of concentration-depen-
dent activity. J. Infect. Dis. 190:1464–1471.
38. Wiederhold, N. P., and R. E. Lewis. 2003. The echinocandin antifungals: an
overview of the pharmacology, spectrum and clinical efficacy. Expert Opin.
Investig. Drugs 12:1313–1333.
39. Wiederhold, N. P., et al. 2007. In vivo efficacy of anidulafungin and caspo-
fungin against Candida glabrata and association with in vitro potency in the
presence of sera. Antimicrob. Agents Chemother. 51:1616–1620.
3260 WIEDERHOLD ET AL. ANTIMICROB. AGENTS CHEMOTHER.
